Jesse Solomon
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/26567_jsolomon_0.jpg?itok=PLBn1SV7)
Filters
Davis Polk Advises Attunity on Its Acquisition by Qlik
Davis Polk is advising Attunity Ltd. on its approximately $560 million acquisition by Qlik Technologies Inc. The transaction, which is expected to close in the second quarter of 2019, is…
Davis Polk Advises Millicom on Its Acquisition of Telefónica Assets
Davis Polk is advising Millicom International Cellular S.A. on its $1.65 billion acquisition of the entire share capital of Telefónica Móviles Panamá, S.A., Telefónica de Costa Rica TC, S.A…
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…
Aetna receives DOJ approval of $77 billion acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk Advises Shire on Its Proposed Acquisition by Takeda
Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…
Shire $2.4 billion sale of its Oncology business to Servier
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…
Aetna $77 billion acquisition by CVS Health
Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…
Davis Polk Advises Metalmark Capital on the Sale of WorldStrides
Davis Polk is advising Metalmark Capital in connection with the sale of WorldStrides. Under the terms of the sale and merger agreement, Metalmark and its co-investors have agreed to sell…